List view / Grid view
In this in-depth focus are articles on what manufacturing challenges must be overcome for regenerative medicine to reach its potential and how automation and digitalisation ensure efficient bioprocessing.
Included in this in-depth focus is a discussion on how to detect and eliminate NDMA impurities in medicines and an article exploring the complexities of sterility assurance, providing manufacturers with guidance.
20 August 2020 | By SUEZ
The new Sievers Eclipse Bacterial Endotoxins Testing (BET) Platform combines ground-breaking technology and ease-of-use to automate endotoxin assay setup without altering reaction biochemistry or compliance. Watch our on-demand webinar to learn more.
Dr Stephane Gobron explores three different ways that manufacturers can use to bring their PPE up to regulatory standard.
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
A new report has outlined that AstraZeneca has been granted protection from product liability claims regarding its COVID-19 vaccine candidate.
Pfizer is to manufacture and supply the investigational COVID-19 treatment remdesivir for Gilead Sciences at one of its facilities.
J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country's government.
President Donald Trump has signed the 'Buy American' executive order, which is meant to reduce drug prices and protect the US from supply chain disruptions.
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
The National Institutes of Health in the US has awarded contracts to seven biomedical companies to develop and manufacture COVID-19 diagnostics.
According to David Bennett, securing and building trust in the label, brand and process of a highly regulated industry player in a complex age will demand a new approach.
Sanofi and GSK have reached an agreement with the UK government to supply up to 60 million doses of their COVID-19 vaccine.
29 July 2020 | By Charles River
In this webinar we discuss the results of our latest study where we evaluated the ruggedness, repeatability and specificity of commercially available rFC products, as well as our own recombinant product in development, against a large panel of endotoxins.
Sandoz plans to invest €150 million and the Austrian government €50 million into integrated antibiotic manufacturing operations at Kundl.
